

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 1 of 2

ATTY. DOCKET NO.
33564-US-PC
APPLICATION NO.
Not Yet Known
APPLICANTBUDAY, ET AL
FILING DATE 10/17/70 19 JUN 2006
Herewith

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	02/46471	6/13/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	2004/020582	3/11/04	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AO	03/034067	4/24/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/M.N./	AR	Neshat et al., "Enhanced Sensitivity of PTEN-Deficient Tumors to Inhibition of FRAP/mTOR", Proceedings of the National Academy of Sciences of the United States of America, Vol. 98, No. 18, pp. 10314-10319 (2001).
/M.N./	AS	Hidalgo et al., "The Rapamycin-Sensitive Signal Transduction Pathway as a Target for Cancer Therapy", Oncogene, Vol. 19, No. 56, pp. 6680-6686 (2000) -- Abstract.
/M.N./	AT	Kwiatkowski et al., "A Mouse Model of TSC1 Reveals Sex-Dependent Lethality from Liver Hemangiomas, and Up-Regulation of p70S6 Kinase Activity in Tsc1 Null Cells", Human Molecular Genetics, Vol. 11, No. 5, pp. 525-534 (2002) -- Abstract.

EXAMINER

/Meera Natarajan/

DATE CONSIDERED

10/30/2007

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
33564-US-P
APPLICATION NO.
Not Yet Known
APPLICANT
BOULAY ET AL.
FILING DATE
Herewith

10/583674
IAP2006/PTO 19 JUN 2006
Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/M.N./	BA	Shi et al., "Enhanced Sensitivity of Multiple Myeloma Cells Containing PTEN Mutations to CCI-779", Cancer Research, Vol. 62, No. 17, pp. 5027-5034 (pp. 2002).
/M.N./	BB	Huang et al., "Resistance to Rapamycin: A Novel Anticancer Drug", Cancer and Metastasis Reviews, Vol. 20, No. 1-2, pp. 69-78 -- Abstract.
/M.N./	BC	Fukazawa et al., "Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase (MEK) Inhibitors Restore Anoikis Sensitivity in Human Breast Cancer Cell Lines with a Constitutively Activated...", Molecular Cancer Therapeutics, Vol. 1, No. 5, pp. 303-309 (2002) -- Abstract.
/M.N./	BD	Dumont et al., "Mechanism of Action of the Immunosuppressant Rapamycin", Life Sciences, Vol. 58, No. 5, pp. 373-395 -- Abstract.
	BE	
	BF	
	BG	
	BH	
	BI	
	BJ	
	BK	
	BL	
	BM	
	BN	

EXAMINER

/Meera Natarajan/

DATE CONSIDERED

10/30/2007

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.